Symptomatic Intracranial Hemorrhage Rates and Intravenous Tissue Plasminogen Activator Treatment Time Windows: Does Treatment Window Make a Difference? (P6.015)

Jeffrey Wagner; Alessandro Orlando; Christopher Fanale; Kathryn McCarthy; Michelle Whaley; Judd Jensen; David Bar-Or

Symptomatic Intracranial Hemorrhage Rates and Intravenous Tissue Plasminogen Activator Treatment Time Windows: Does Treatment Window Make a Difference? (P6.015)

Jeffrey Wagner
, Alessandro Orlando
, Christopher Fanale
, Kathryn McCarthy
, Michelle Whaley
, Judd Jensen
, David Bar-Or

Blue Sky Neurosciences Englewood CO United States
Trauma Research Swedish Medical Center Englewood CO United States
Neurology Blue Sky Neurology Englewood CO United States
Neurology Swedish Medical Center Englewood CO United States
Swedish Medical Center Englewood CO United States

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neurology
Volume	86
State	Published - Apr 5 2016
Externally published	Yes

Disciplines

Medicine and Health Sciences
Endocrinology, Diabetes, and Metabolism
Internal Medicine

Cite this

@article{564203609d8f4d8db0a5843385bd212e,

title = "Symptomatic Intracranial Hemorrhage Rates and Intravenous Tissue Plasminogen Activator Treatment Time Windows: Does Treatment Window Make a Difference? (P6.015)",

author = "Jeffrey Wagner and Alessandro Orlando and Christopher Fanale and Kathryn McCarthy and Michelle Whaley and Judd Jensen and David Bar-Or",

note = "Objective: Determine the odds of suffering a sICH if treated with IV-tPA <3h, compared to 3-4.5h. Background: There are no data to support the hypothesis of an increased risk of symptomatic ICH (sICH) with the later 3-4.5h IV-tPA treatment window, compared to the <3h window. Methods: 6-year retrospective observational study.",

year = "2016",

month = apr,

day = "5",

language = "American English",

volume = "86",

journal = "Neurology",

}

TY - JOUR

T1 - Symptomatic Intracranial Hemorrhage Rates and Intravenous Tissue Plasminogen Activator Treatment Time Windows: Does Treatment Window Make a Difference? (P6.015)

AU - Wagner, Jeffrey

AU - Orlando, Alessandro

AU - Fanale, Christopher

AU - McCarthy, Kathryn

AU - Whaley, Michelle

AU - Jensen, Judd

AU - Bar-Or, David

N1 - Objective: Determine the odds of suffering a sICH if treated with IV-tPA <3h, compared to 3-4.5h. Background: There are no data to support the hypothesis of an increased risk of symptomatic ICH (sICH) with the later 3-4.5h IV-tPA treatment window, compared to the <3h window. Methods: 6-year retrospective observational study.

PY - 2016/4/5

Y1 - 2016/4/5

UR - https://n.neurology.org/content/86/16_Supplement/P6.015

M3 - Article

VL - 86

JO - Neurology

JF - Neurology

ER -

Symptomatic Intracranial Hemorrhage Rates and Intravenous Tissue Plasminogen Activator Treatment Time Windows: Does Treatment Window Make a Difference? (P6.015)

Disciplines

Other files and links

Cite this